Rauner M - Search Results

1

Stimulation of bone formation by monocyte-activator functionalized graphene oxide in vivo.

Bordoni V, Reina G, Orecchioni M, Furesi G, Thiele S, Gardin C, Zavan B, Cuniberti G, Bianco A, Rauner M, Delogu LG. Bordoni V, et al. Among authors: rauner m. Nanoscale. 2019 Nov 7;11(41):19408-19421. doi: 10.1039/c9nr03975a. Epub 2019 Aug 6. Nanoscale. 2019. PMID: 31386739

2

High serum levels of Dickkopf-1 are associated with a poor prognosis in prostate cancer patients.

Rachner TD, Thiele S, Göbel A, Browne A, Fuessel S, Erdmann K, Wirth MP, Fröhner M, Todenhöfer T, Muders MH, Kieslinger M, Rauner M, Hofbauer LC. Rachner TD, et al. Among authors: rauner m. BMC Cancer. 2014 Sep 2;14:649. doi: 10.1186/1471-2407-14-649. BMC Cancer. 2014. PMID: 25182503 Free PMC article.

3

WNT5A has anti-prostate cancer effects in vitro and reduces tumor growth in the skeleton in vivo.

Thiele S, Göbel A, Rachner TD, Fuessel S, Froehner M, Muders MH, Baretton GB, Bernhardt R, Jakob F, Glüer CC, Bornhäuser M, Rauner M, Hofbauer LC. Thiele S, et al. Among authors: rauner m. J Bone Miner Res. 2015 Mar;30(3):471-80. doi: 10.1002/jbmr.2362. J Bone Miner Res. 2015. PMID: 25224731 Free article.

4

Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins.

Göbel A, Browne AJ, Thiele S, Rauner M, Hofbauer LC, Rachner TD. Göbel A, et al. Among authors: rauner m. Breast Cancer Res Treat. 2015 Dec;154(3):623-31. doi: 10.1007/s10549-015-3624-8. Epub 2015 Oct 29. Breast Cancer Res Treat. 2015. PMID: 26515701

5

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin.

Benad-Mehner P, Thiele S, Rachner TD, Göbel A, Rauner M, Hofbauer LC. Benad-Mehner P, et al. Among authors: rauner m. J Bone Oncol. 2013 Nov 15;3(1):18-24. doi: 10.1016/j.jbo.2013.11.001. eCollection 2014 Mar. J Bone Oncol. 2013. PMID: 26909290 Free PMC article.

6

p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells.

Browne AJ, Göbel A, Thiele S, Hofbauer LC, Rauner M, Rachner TD. Browne AJ, et al. Among authors: rauner m. Cell Death Dis. 2016 Feb 25;7(2):e2119. doi: 10.1038/cddis.2016.32. Cell Death Dis. 2016. PMID: 26913608 Free PMC article.

7

Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells.

Göbel A, Thiele S, Browne AJ, Rauner M, Zinna VM, Hofbauer LC, Rachner TD. Göbel A, et al. Among authors: rauner m. Cancer Lett. 2016 May 28;375(1):162-171. doi: 10.1016/j.canlet.2016.03.004. Epub 2016 Mar 8. Cancer Lett. 2016. PMID: 26968247

8

WNT5A and Its Receptors in the Bone-Cancer Dialogue.

Thiele S, Rachner TD, Rauner M, Hofbauer LC. Thiele S, et al. Among authors: rauner m. J Bone Miner Res. 2016 Aug;31(8):1488-96. doi: 10.1002/jbmr.2899. J Bone Miner Res. 2016. PMID: 27355180 Free article. Review.

9

Bone Formation and the Wnt Signaling Pathway.

Rauner M, Rachner TD, Hofbauer LC. Rauner M, et al. N Engl J Med. 2016 Nov 10;375(19):1902. doi: 10.1056/NEJMc1609768. N Engl J Med. 2016. PMID: 27959644 Free article. No abstract available.

10

Role of WNT5A receptors FZD5 and RYK in prostate cancer cells.

Thiele S, Zimmer A, Göbel A, Rachner TD, Rother S, Fuessel S, Froehner M, Wirth MP, Muders MH, Baretton GB, Jakob F, Rauner M, Hofbauer LC. Thiele S, et al. Among authors: rauner m. Oncotarget. 2018 Jun 5;9(43):27293-27304. doi: 10.18632/oncotarget.25551. eCollection 2018 Jun 5. Oncotarget. 2018. PMID: 29930766 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

228 results

Search Page